Data elements by category

Figures  |  Boxes  |  Tables

Figures


Figure 1: Lifetime, last year and last month prevalence of cannabis use among 15- to 16-year-old school students in 2003

Figure 2: Development of school policies

Figure 3: Current use (last month) of cannabis among young adults (aged 15–24), measured by national surveys

Figure 4: Trends in recent use (last year) of cannabis among young adults (aged 15–34), measured by national surveys (1)

Figure 5: Lifetime prevalence of cannabis use among 15- to 16-year-old school students reported in the 1995, 1999 and 2003 rounds of the ESPAD survey

Figure 6: Recent use (last year) of amphetamines among young adults at selected ages, 15–34 and 15–24, measured by population surveys

Figure 7: Lifetime prevalence and recent use (last year) of ecstasy among young adults at selected ages, 15–34 and 15–24, measured by population surveys

Figure 8: Trends in recent use (last year) of amphetamines among young adults (aged 15–34), measured by population surveys (1)

Figure 9: Trends in recent use (last year) of ecstasy among young adults (aged 15–34), measured by population surveys (1)

Figure 10: Recent use (last year) of cocaine among all young adults and among young males, measured by national surveys

Figure 11: Trends in recent use (last year) of cocaine among young adults (aged 15–34), measured by population surveys (1)

Figure 12: Estimates of the prevalence of problem drug use, 1999–2003 (rate per 1 000 population aged 15–64)

Figure 13: National and local estimates of the prevalence of problem drug use, 1999–2003 (rate per 1 000 population aged 15–64)

Figure 14: New outpatient clients injecting opiates as a proportion of the total number of new opiates clients by country, 2003

Figure 15: AIDS cases by transmission group and year of diagnosis (1987–2003) adjusted for reporting delays, EU

Figure 16: National and local estimates of HCV prevalence among injecting drug users, 2002–2003

Figure 17: Notified cases of hepatitis C, percentage of cases reported as IDU, 1992–2003

Figure 18: Introduction of needle and syringe programmes in 23 EU countries, Norway and Bulgaria

Figure 19: Trends in mean age of acute drug-related deaths victims in some of the EU-15 Member States, 1990–2001/03

Figure 20: Overall trend in acute drug-related deaths in the EU-15 Member States and trend in the proportion of drug-related death victims under 25 years old, 1990–2003

Figure 21: Overall trend in acute drug-related deaths in new Member States and candidate countries and trend in proportion of victims under 25 years old, 1996–2003

Figure 22: HIV infections newly diagnosed in injecting drug users in selected EU countries, Russia and Ukraine, by year of report

Figure 23: Recent (last year) use of cannabis among young adults (15–34 years old) in Europe and the USA

Figure 24: Recent (last year) use of ecstasy among young adults (15–34 years old) in Europe and the USA

Figure 25: Recent (last year) use of cocaine among young adults (15–34 years old) in Europe and the USA